

Title (en)
COMPOSITIONS AND METHODS FOR THERAPEUTIC TREATMENT

Title (de)
ZUSAMMENSETZUNGEN UND VERFAHREN FÜR EINE THERAPEUTISCHE BEHANDLUNG

Title (fr)
COMPOSITIONS ET PROCEDES POUR TRAITEMENT THERAPEUTIQUE

Publication
EP 1551452 A4 20060830 (EN)

Application
EP 03742338 A 20030630

Priority
• US 0320604 W 20030630
• US 18902502 A 20020701

Abstract (en)
[origin: WO2004002528A1] The present invention relates to compositions utilizing an agent and an antibody, or fragment thereof. In these compositions, the agents, including agents such as anti-cancer, anti-metastasis, anti-leukemia, anti-disease, anti-adhesion, anti-thrombosis, anti-restenosis, anti-autoimmune, anti-aggregation, anti-bacterial, anti-viral, and anti-inflammatory agents, can be complexed or combined with or conjugated to the antibodies, or fragments thereof. In addition, the agent and/or the antibody, or fragment thereof, can be present in the composition in a sub-clinical amount, which is an amount that is less than the amount of the agent generally found to be clinically effective when the agent is administered alone. Preferably, in these compositions of the present invention, the agent is an anthracycline or a derivative thereof, e.g., doxorubicin (adriamycin) or a derivative thereof.

IPC 1-7
A61K 39/395; **A61K 51/00**; **A61K 38/00**; **A61K 39/00**

IPC 8 full level
A61K 45/00 (2006.01); **A61K 31/704** (2006.01); **A61K 39/395** (2006.01); **A61K 47/48** (2006.01); **A61K 51/00** (2006.01); **A61P 7/02** (2006.01); **A61P 9/00** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 35/02** (2006.01); **A61P 35/04** (2006.01); **A61P 37/06** (2006.01); **A61P 43/00** (2006.01); **C07K 16/30** (2006.01)

CPC (source: EP KR)
A61K 31/704 (2013.01 - EP); **A61K 39/00** (2013.01 - KR); **A61K 39/395** (2013.01 - KR); **A61K 39/39558** (2013.01 - EP); **A61K 47/6809** (2017.07 - EP); **A61K 47/6849** (2017.07 - EP); **A61P 7/02** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **A61P 35/04** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 16/3061** (2013.01 - EP); **A61K 2039/505** (2013.01 - EP); **C07K 2317/622** (2013.01 - EP)

Citation (search report)
• [X] WO 0187334 A1 20011122 - PHARMACIA & UPJOHN SPA [IT], et al
• [X] WO 0185205 A1 20011115 - UNIV TSINGHUA [CN], et al
• [X] WO 9811918 A1 19980326 - RES CORP TECHNOLOGIES INC [US]
• [PX] WO 02053700 A2 20020711 - BIO TECHNOLOGY GENERAL CORP [US]
• [PX] WO 02059264 A2 20020801 - BIO TECHNOLOGY GENERAL CORP [US], et al
• See references of WO 2004002528A1

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2004002528 A1 20040108; **WO 2004002528 A9 20041118**; AU 2003279657 A1 20040119; BR 0312484 A 20080108; CA 2491427 A1 20040108; CN 1678348 A 20051005; EP 1551452 A1 20050713; EP 1551452 A4 20060830; IL 166062 A0 20060115; JP 2005534679 A 20051117; KR 20050059001 A 20050617; MX PA05000271 A 20050331; PL 374431 A1 20051017; RU 2005101622 A 20060127

DOCDB simple family (application)
US 0320604 W 20030630; AU 2003279657 A 20030630; BR 0312484 A 20030630; CA 2491427 A 20030630; CN 03820441 A 20030630; EP 03742338 A 20030630; IL 16606204 A 20041230; JP 2004518133 A 20030630; KR 20047021602 A 20041230; MX PA05000271 A 20030630; PL 37443103 A 20030630; RU 2005101622 A 20030630